Suven Life Sciences is set to present its differentiated central nervous system (CNS) clinical candidates and partnering strategies at the BIO International Convention 2026 in San Diego from June 22-25, 2026. The company aims to engage with global pharmaceutical and biotechnology firms to explore out-licensing and co-development initiatives for its clinical-stage assets targeting significant unmet medical needs.

Participation at BIO International Convention 2026

The BIO International Convention serves as a key platform for life sciences companies to engage with potential collaborators and investors. Suven Life Sciences will welcome delegates and partners to Booth #6154, where it will showcase its portfolio, including late-stage clinical assets for indications such as agitation in dementia of Alzheimer's type, major depressive disorder, narcolepsy, and cognitive impairment associated with Parkinson's disease. The company has scheduled 62 partnering meetings over the four days of the event.

CNS Pipeline and Strategic Outreach

Suven Life Sciences' delegation includes senior leaders such as Venkat Jasti, Chairman and Managing Director, and Ramakrishna Nirogi, President and Chief Scientific Officer. The company highlighted the depth of its portfolio, citing positive Phase 2b results for Ropanicant in major depressive disorder, promising Phase-1 data for SUVN-I6107, and ongoing Phase-3 programs for Masupirdine and Samelisant. The goal is to accelerate the development and commercialization of these assets through strategic alliances.

Key Clinical Candidates

• Ropanicant (SUVN-911): An α4β2 receptor antagonist for major depressive disorder. Positive topline results from the Phase-2b trial were announced on June 17, 2026, with a global Phase-3 study planned to start in H1-2027.
• Masupirdine (SUVN-502): A 5-HT6 receptor antagonist for agitation in dementia of Alzheimer's type. The global Phase-3 (AWAKE) study is 95% enrolled, with topline results expected in Q2-2027.
• Samelisant (SUVN-G3031): An H3 inverse agonist for narcolepsy. The global Phase-3 study has been initiated, with topline results expected in Q2-2028.
• Usmarapride (SUVN-D4010): A 5-HT4 receptor partial agonist for cognitive disorders. A Phase-2 study is planned following a safe Phase-1 study.
• SUVN-16107: A muscarinic M1 positive allosteric modulator for cognitive disorders. A Phase-2 study is in planning following favourable Phase-1 results.

Suven Life Sciences confirmed that shares held by its promoters and promoter group remained unencumbered throughout the financial year ended March 31, 2026. The disclosure ensures that no equity was pledged directly or indirectly by the promoters during FY26, signaling stability in the company's shareholding structure.

The confirmation was submitted to the National Stock Exchange of India Limited and BSE Limited by Venkateswarlu Jasti on behalf of the promoter(s) and promoter group. The filing was made under Regulation 31(4) of the SEBI (Substantial Acquisition of Shares & Takeover) Regulations, 2011, which mandates periodic disclosures regarding share encumbrances.

Disclosure Details

The communication explicitly stated that there were no instances of pledging or encumbrance of shares by the promoters during the specified period. This information was provided for the record of the exchanges and the company's Audit Committee.

The disclosure was addressed to the Listing Department of the NSE and the Department of Corporate Services of the BSE. A copy of the letter was also forwarded to the Audit Committee of Suven Life Sciences .